A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
Here, we provide a reliable approach for isolating low- and normal-density neutrophils from whole blood using magnetic isolation (negative selection) and discontinuous density gradient medium. It ensures untouched isolation of high-purity cells (≥93%), facilitating accurate downstream analysis of neutrophil subpopulations, crucial for understanding their roles in health and disease.
Emerging research shows that the circulating neutrophil population in humans consists of diverse subtypes and should not be studied as a single population, as has been done historically. In particular, low-density and normal-density neutrophils (LDNs, NDNs) have been shown to have functionally and metabolically distinct profiles, a factor that must be considered when publishing neutrophil research. Here, we present a modified method for the untouched isolation and separation of LDNs and NDNs from whole blood.
The density gradient medium (1.135 g/mL) is combined at 9:10 with 10x PBS. Specific density gradients of 55%, 70%, and 81% are subsequently made by combining the 100% density gradient medium with 1x phosphate-buffered saline (PBS). Neutrophils isolated from 12 mL of peripheral whole blood obtained from consented donors using a negative selection-based magnetic isolation kit are resuspended in the 55% fraction. A volume of 3 mL of the 81% and 70% fractions is layered into a 15 mL tube, followed by the 55% fraction containing total neutrophils. The density gradients are then centrifuged at 720 x g for 30 min. Two distinct bands are obtained at the 55%/70% interface (LDNs) and 70%/81% interface (NDNs). The cells are carefully pipetted into separate tubes and washed using PBS. The purity of the isolated fractions is determined using flow cytometry. Both LDNs and NDNs were defined as CD14lo CD15+ SSChi by flow cytometry. Isolation purity was calculated at ≥93% of viable cells for both types.
This method provides a reliable and efficient approach for separating LDN and NDNs from peripheral blood, ensuring high purity and viability of the isolated cells. Enhancing the precision of neutrophil isolation facilitates more accurate downstream analyses of these distinct neutrophil subpopulations. These are critical for advancing our understanding of neutrophil heterogeneity and its implications in various physiological and pathological contexts.
Neutrophils are granular immune cells and the most abundant leukocyte in peripheral blood, constituting about 50%-70% of leukocytes on average. They develop in the bone marrow from granulocyte-monocyte precursors (GMPs), which in turn develop from hematopoietic progenitor cells (HPCs) in the presence of granulocyte colony-stimulating factor (G-CSF). At homeostasis, they have a lifespan of ~24 h, but studies have shown that their lifespan can be extended under specific physiological conditions and their associated microenvironments such as chronic immune activation1, inflammation1, and even tissue residency in steady state2. Neutrophils have long been considered the first line of defense against pathogens and elicit their anti-microbial effects through 3 major effector functions -- degranulation, phagocytosis, and neutrophil extracellular trap (NET) activation and release (NETosis).
Most studies on neutrophil function and biology examine outcomes for the total neutrophil population. However, from studies in cancer settings delineating N1 (anti-tumor)/ N2 (pro-tumor) subtypes to the classification of neutrophils based on maturity, disease, and physiological state, and even cellular density (low density and normal density neutrophils), it has become increasingly apparent that the human neutrophil population constitutes phenotypically diverse subtypes. Whether the existence of these neutrophil subtypes can be attributed to being completely distinct cell types or due to the complex nature of plasticity, there exists a growing body of literature on atypical neutrophils and presents a compelling opportunity to study low-density neutrophils separate from normal-density neutrophils3.
Described for the first time in SLE patients as a pro-inflammatory neutrophil subset4, LDNs have since been identified in chronic diseases, pregnancy, and even in healthy circulation, in pro-inflammatory as well as suppressive capacities5,6,7,8. LDNs are found concurrently with peripheral blood mononuclear cells (PBMCs) when whole blood is centrifuged over density gradient media. Their specific density corresponds to approximately 1.077 g/mL, compared to NDNs at 1.083 g/mL9. While there is still considerable debate on the subject, there exists speculation that LDNs resemble a more immature granulocyte phenotype (similar to promyelocytes and myelocytes, with a density below 1.080 g/mL)9,10. Others still speculate that there are both mature and immature LDN phenotypes depending on the presence or absence of disease11,12,13. Nevertheless, LDNs have also been detected in healthy individuals; however, their inclusion in some studies is limited due to the difficulty in isolating them in sufficient numbers5.
This study aimed to isolate these two populations in quantities that would allow us to perform downstream in situ metabolic experiments (minimum 0.5 × 106 cells/mL). In doing so, an existing protocol5 was optimized with commonly reported phenotypic markers13,14 that provide the best outcome for isolating and characterizing LDNs and NDNs from whole blood (Figure 1A).
Blood samples were collected with informed consent from healthy participants. The study received approval from the Research Ethics Committee of both St. James's Hospital and Tallaght University Hospital.
1. Preparation of density gradient medium, isotonic working solutions fractions and cell separation buffer
2. Isolation of neutrophils from whole blood using negative selection
3. Separation of low-density neutrophils (LDNs) and normal-density neutrophils (NDNs) from the total neutrophil population
4. Phenotyping of isolated LDN and NDN
The successful layering of total neutrophils over the density gradient medium can be observed in Figure 1B. Two distinct bands should be obtained. If mixing of the gradients occurs, or the number of total neutrophils layered per tube is high (greater than roughly 5-6 × 106), the bands will look diffuse (Figure 1C), and the risk of the two neutrophil subtypes mixing increases significantly. To avoid the latter, we recommend layering up to 5-6...
Here, we present an optimized method of splitting the total neutrophil population into low- density and normal-density neutrophils, together with phenotypic characterization of each cell type using flow cytometry adapted from previous methods5.
This protocol is based on the isolation of LDNs and NDNs from whole blood. A crucial step is that total neutrophils are isolated through negative selection methods. Positive selection methods involve the use of antibodies that bi...
The authors have no disclosures.
This work was funded by the Health Research Board EIA-2024-002 and the Royal City of Dublin Hospital Trust. We would like to thank Dr. Lorraine Thong and Dr. Kevin Brown for their assistance in collecting samples from healthy donors for this manuscript.
Name | Company | Catalog Number | Comments |
14 mL Polypropylene Round-Bottom Tube (17 x 100 mm) | Corning Science | 352059 | |
APC anti-human CD14 (63D3) | BioLegend | 367118 | |
Brilliant Violet 421 anti-human CD10 (25 tests) | BioLegend | 312217 | |
Dulbecco's Phosphate-Buffered Saline | Sigma | D8537-1L | |
EasyEights EasySep Magnet | StemCell Technologies | #18103 | |
EasySep Buffer (cell separation buffer) | StemCell Technologies | #20144 | |
EasySep Direct Human Neutrophil Isolation Kit | StemCell Technologies | #19666 | |
FcR Blocking Reagent, human | Miltenyi Biotec | 130-059-901 | |
FITC anti-human CD16 (3G8) | BioLegend | 302005 | |
OneComp eBeads Compensation Beads | eBioscience Inc. | 01-1111-42 | |
PE/Cy7 anti-human CD86 (BU63) | BioLegend | 374209 | |
PE/Dazzle 594 anti-human CD15 (SSEA-1) | BioLegend | 323037 | |
Phosphate-Buffered Saline Tablets | Gibco | 18912-014 | |
Zombie NIR Fixable Viability Kit | BioLegend | 423105 |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved